Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Jul 13, 2006


Title: Methods for Blocking Adipocyte Differentiation and Triglyceride Accumulation with G-Alpha-i3 Inhibitors

Number: 20060154882

Filed: June 10, 2003 PCT Filed: June 10, 2003

Lead Inventor: Eric Marcusson, Isis Pharmaceuticals

According to its abstract, the patent application covers "methods for blocking adipocyte differentiation and triglyceride accumulation with inhibitors of G-alpha-i3. G-alpha-i3 inhibitors … include small molecules, antibodies, peptides (including dominant negative peptides) and antisense compounds, including ribozymes, inhibitory RNA molecules including siRNA molecules, and antisense oligonucleotides."

Title: Compounds for Targeting Hepatocytes

Number: 20060154867

Filed: Jan. 20, 2006

Lead Inventor: Alexander Sokoloff, Mirus

The patent application, its abstract states, covers "compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro."

Title: Efficient Gene Suppression Using a Transfer RNA Promoter in Herpes Virus Vectors to Deliver Small Interference RNAs

Number: 20060154370

Filed: Jan. 7, 2006

Inventor: Yuzhi Chen, University of Arkansas

"The invention provides herpes virus nucleic acid vectors for expressing shRNAs in mammalian cells and thereby silencing target genes," the patent application's abstract states. "The vectors include a herpes virus packaging signal sequence; a herpes virus origin of replication; a segment expressing a light-emitting marker; and a transfer RNA promoter upstream of a restriction endonuclease recognition sequence. A segment encoding an shRNA can be cloned into the restriction endonuclease recognition sequence," the abstract adds. "Thus, the invention also provides vectors containing: a herpes virus packaging signal sequence; a herpes virus origin of replication; a segment expressing a light-emitting marker; and a transfer RNA promoter linked to a segment encoding a short hairpin RNA that is adapted to degrade in vivo to a small interference RNA that is complementary to a segment of a target gene."

Title: Soluble RNA Polymerase Protein and Methods for the Use Thereof

Number: 20060154237

Filed: Oct. 17, 2003 PCT Filed: Oct. 17, 2003

Lead Inventor: Eugene Makeyev, RNA-Line Oy

According to the patent application's abstract, the invention comprises "a polymerase protein originating from a eukaryotic cell and involved in the RNA silencing pathway … in a purified soluble form that possesses a detectable RNA polymerization activity. This polymerase is useful in methods and kits for in vitro RNA synthesis."

The abstract adds that "a polymerase of the invention copies ssRNA templates to produce two types of reaction products: short and long RNA copies. It can also copy ssDNA templates. The polymerization does not require a primer for the initiation of RNA synthesis, although RNA synthesis can be also initiated in the presence of a primer. In addition to standard nucleotides polymerase of this invention also accepts a number of modified nucleotides," it states. "The polymerase is useful in many downstream applications such as production of labeled RNA probes or generation of trigger RNA molecules to induce RNA interference effects in living cells or suitable in vitro systems."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.